Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Position Increased by Jennison Associates LLC

Jennison Associates LLC lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 47.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 2,178,580 shares of the company's stock after purchasing an additional 698,712 shares during the quarter. Jennison Associates LLC owned about 5.73% of Tarsus Pharmaceuticals worth $71,653,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Quest Partners LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter worth about $61,000. Canada Pension Plan Investment Board acquired a new position in shares of Tarsus Pharmaceuticals during the second quarter worth $114,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Tarsus Pharmaceuticals by 33.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock worth $166,000 after purchasing an additional 1,530 shares in the last quarter. Dark Forest Capital Management LP purchased a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at $202,000. Finally, SG Americas Securities LLC grew its holdings in Tarsus Pharmaceuticals by 87.5% during the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock valued at $238,000 after purchasing an additional 3,379 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TARS. William Blair upgraded shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. The Goldman Sachs Group lifted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th. Finally, Oppenheimer increased their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $54.20.

Tarsus Pharmaceuticals Stock Down 2.7 %

Shares of NASDAQ:TARS opened at $45.30 on Thursday. Tarsus Pharmaceuticals, Inc. has a 1-year low of $15.60 and a 1-year high of $52.99. The company's fifty day moving average is $38.71 and its two-hundred day moving average is $32.77. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -12.23 and a beta of 1.00.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.